In a world where cancer often feels like an insurmountable foe, a glimmer of hope has emerged—and it’s bigger than you might think. For the first time ever, 70% of cancer patients are surviving at least five years after their diagnosis, according to the American Cancer Society’s latest report. But here’s where it gets even more remarkable: this isn’t just a small victory; it’s a testament to decades of relentless research and innovation. Since the mid-1970s, when the five-year survival rate was a mere 49%, we’ve seen a staggering leap forward, turning what was once a death sentence into a manageable condition for many.
This progress is particularly striking for some of the deadliest cancers. Take myeloma, liver cancer, and lung cancer, for instance. Survival rates for these have soared—myeloma from 32% to 62%, liver cancer from 7% to 22%, and lung cancer from 15% to 28%. Even patients with advanced cancers are seeing dramatic improvements, with five-year survival rates doubling from 17% to 35% across the board. And this is the part most people miss: for those diagnosed with advanced lung cancer, survival rates have jumped from 2% to 10% for metastatic cases—a tenfold increase.
But let’s not get ahead of ourselves. While these advancements are cause for celebration, they also highlight a stark reality: not everyone is benefiting equally. Marginalized communities, particularly Native Americans, continue to face disproportionately higher cancer mortality rates. For example, Native Americans are twice as likely as white individuals to die from kidney, liver, stomach, and uterine cervix cancers. This disparity isn’t just a statistic—it’s a call to action. As Ahmedin Jemal, a senior author of the report, points out, socioeconomic factors and lack of access to quality care are still major barriers. The question is: are we doing enough to bridge this gap?
Now, for the sobering part: cancer remains the second-leading cause of death in the U.S., with over 2 million new diagnoses and 600,000 deaths expected in 2026. The incidence of cancers like breast, prostate, oral, pancreas, and endometrial cancers is on the rise, and environmental factors like microplastics and air pollution are adding fuel to the fire. And here’s where it gets controversial: just as we’re making strides, funding cuts to cancer research and healthcare access threaten to undo decades of progress. The Trump administration’s proposed reductions in research funding could stall breakthroughs and reverse the gains we’ve fought so hard to achieve.
So, what’s the takeaway? Investment in cancer research isn’t just important—it’s lifesaving. From early detection to cutting-edge treatments, every dollar spent has contributed to the survival gains we’re seeing today. But the future is far from certain. Will policymakers prioritize these investments, or will they let progress slip away? And more importantly, how can we ensure that these advancements reach everyone, regardless of race or socioeconomic status?
This report isn’t just a collection of numbers; it’s a reminder of what’s possible when we commit to a cause. But it’s also a challenge. Are we ready to keep fighting, or will we let this momentum fade? The choice is ours—and the stakes couldn’t be higher.
